{"id":933952,"date":"2026-02-04T07:18:32","date_gmt":"2026-02-04T12:18:32","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-teams-up-with-kasey-keller-to-share-his-lymphoma-journey-with-breyanzi\/"},"modified":"2026-02-04T07:18:32","modified_gmt":"2026-02-04T12:18:32","slug":"bristol-myers-squibb-teams-up-with-kasey-keller-to-share-his-lymphoma-journey-with-breyanzi","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/bristol-myers-squibb-teams-up-with-kasey-keller-to-share-his-lymphoma-journey-with-breyanzi\/","title":{"rendered":"Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi"},"content":{"rendered":"

<\/p>\n

Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi<\/b><\/p>\n

Soccer Hall-of-Famer is speaking out for the first time about his private battle with lymphoma and treatment with <\/i>Breyanzi in honor of World Cancer Day<\/i><\/b><\/p>\n

Breyanzi is a personalized, CD19-directed CAR T cell therapy made from a patient\u2019s own T cells and is FDA-approved for five different cancer types, the broadest set of indications of any CD19-directed CAR T cell therapy<\/i><\/b><\/p>\n

PRINCETON, N.J.–(BUSINESS WIRE<\/a>)–Bristol Myers Squibb<\/a> (NYSE: BMY) today announced they have teamed up with renowned goalkeeper and sports commentator Kasey Keller, who is publicly sharing his personal experience with non-Hodgkin lymphoma (NHL) for the first time. His story details a long and challenging treatment journey that ultimately led him to Breyanzi<\/i>\u00ae<\/sup> (lisocabtagene maraleucel; liso-cel), a personalized CD19-directed CAR T cell therapy made from a patient\u2019s own T cells and administered as a one-time infusion*. Through this collaboration, Kasey aims to empower and inform others navigating their own blood cancer diagnosis, drawing from his unique experience, because with Breyanzi<\/i>, Cure is the Goal**<\/sup><\/i>.<\/p>\n

This press release features multimedia. View the full release here: https:\/\/www.businesswire.com\/news\/home\/20260202949740\/en\/<\/a><\/p>\n

\"Kasey<\/p>\n

Kasey Keller Photo: Axel Alarcon and Alan Alarcon<\/p>\n<\/div>\n

\nPlease see the Important Safety Information section below, including Boxed WARNINGS<\/b> for Breyanzi<\/i> regarding Cytokine Release Syndrome (CRS), Neurologic Toxicities, and Secondary Hematological Malignancies.<\/p>\n

\nKasey Keller is a former U.S. Men\u2019s National Team goalkeeper and three-time U.S. Soccer Athlete of the Year. Kasey holds the record as the most-capped goalkeeper for the U.S. Men\u2019s National Team. Kasey retired from soccer in 2011 after over two decades on the field. Kasey is now a sports broadcaster.<\/p>\n

\nAfter being diagnosed with cancer in 2010, Kasey cycled through several treatments over the years, often finding only temporary relief. It wasn\u2019t until after receiving one-time treatment* Breyanzi <\/i>under the recommendation of his doctor that his outcome shifted. Finding a treatment that worked allowed him to reflect on the decade of uncertainty he had been navigating. Throughout this journey, he kept his experience private, sharing updates only with close friends and family as he focused on managing each new step. He is now choosing to speak openly about this experience through a new collaboration with Bristol Myers Squibb and Breyanzi<\/a><\/i>. Kasey hopes his story helps others feel more prepared to engage in conversations about their own care.<\/p>\n

\n\u201cThroughout my career, I was trained to stay focused, stay ready, and never give up. But when I was diagnosed with lymphoma, I had to find a whole new kind of resilience,\u201d said Keller. \u201cGoing through lymphoma and treatment with Breyanzi<\/i> was unfamiliar territory, and I leaned heavily on my doctors, my family, and the mindset I\u2019ve carried my entire life. I\u2019m sharing my story because no one should have to navigate this alone. If hearing what I went through helps someone else feel empowered to take their next step, then it\u2019s worth it.\u201d<\/p>\n

\nThis partnership launches on World Cancer Day, a moment that highlights the experiences of people living with cancer and the importance of understanding available treatment options. NHL is a type of blood cancer that starts in the lymphatic system, which is a key part of the body’s immune system. It is one of the most common cancers worldwide, accounting for about 4% of all cancer diagnoses. Despite the transformative potential of cell therapy, only about 2 in 10 eligible patients receive it, due to the complex logistical and geographic barriers affecting patients and providers. This underscores a critical need for greater awareness and education, which Kasey\u2019s story aims to address.<\/p>\n

\n\u201cEvery day we see the strength and resilience of those living with blood cancer. We are grateful to Kasey for sharing his story, which reflects the experience of so many patients affected by lymphoma,\u201d said Lynelle B. Hoch<\/a>, president, Cell Therapy Organization, Bristol Myers Squibb. \u201cKasey\u2019s story underscores the importance of helping patients better understand the potential promise of CAR T cell therapy. Knowing cure is the goal, we hope to inspire patients to talk to their doctors and explore treatment options that would best work for them.\u201d<\/p>\n

\nLearn more about Kasey\u2019s story at BreyanziWithin.com<\/a> and how he worked with his doctors to turn the tables on lymphoma \u2014 because, with Breyanzi<\/i>, Cure is The Goal**<\/sup>.<\/p>\n

*The treatment process includes blood collection, CAR T cell creation, potential bridging therapy, lymphodepletion, administration, and side-effect monitoring.<\/i><\/p>\n

**At a 3-year follow-up, <\/i>Breyanzi reduced the risk of events on average by 62% (range between 46% and 74%) compared to standard of care.<\/i><\/p>\n

About Breyanzi<\/i><\/span><\/b><\/p>\n

Breyanzi<\/i> is a chimeric antigen receptor (CAR) T cell therapy. In certain types of lymphoma, Breyanzi<\/i> may be used after a person\u2019s initial treatment has not worked, or their cancer has returned. Breyanzi<\/i> is different from other cancer medicines because it is made from a person\u2019s own T cells, which are collected and genetically modified to become CAR T cells that recognize and attack your lymphoma.<\/p>\n

Breyanzi<\/i> is approved in the U.S. for the treatment of relapsed or refractory large B-cell lymphoma (LBCL) after at least one prior line of therapy, has received accelerated approval for the treatment of relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) after at least two prior lines of therapy, relapsed or refractory follicular lymphoma (FL) after two or more prior lines of systemic therapy, and is approved for the treatment of relapsed or refractory mantle cell lymphoma (MCL) after at least two prior lines of systemic therapy.<\/p>\n

\nBristol Myers Squibb\u2019s clinical development program for Breyanzi<\/i> includes clinical studies in several types of lymphoma. For more information, visit clinicaltrials.gov<\/a>.<\/p>\n

Breyanzi<\/span><\/i> U.S. FDA-Approved Indications<\/span><\/b><\/p>\n

\nBREYANZI is a prescription medicine used to treat certain types of non-Hodgkin lymphoma:<\/p>\n